Diametric Capital’s Vir Biotechnology VIR Stock Holding History

Diametric Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,832	Closed	-$407K	–	348
2022 Q1	$407K	Buy	+15,832	New	+$470K	0.22%	122

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Diametric Capital's VIR Position: Q2 2022 in Review

Diametric Capital sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 15,832 shares — an estimated $407K sold.

Diametric Capital first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $407K in Q1 2022. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

Diametric Capital reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
Diametric Capital sold 15,832 Vir Biotechnology shares in Q2 2022, an estimated $407K.
Diametric Capital first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
Diametric Capital's Vir Biotechnology position peaked at $407K in Q1 2022.
212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Diametric Capital's 13F filing for Q2 2022, filed 15 Aug 2022.